

## West London Performance in Initiation Q4 2014/15

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA* and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA* and First Patient	Benchmark Met	Comments
143780/LNW	To evaluate the safety and efficacy of 2 fixed doses of EVP-6124	29/09/2014	29/09/2014	Yes	06/11/2014	0	38	38	Yes	

\*VRA stands for Valid Research Application

## West London Performance in Delivery Q4 2014/15

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
51752	13/LO/1758	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).	Available	12	Available	10/09/2016	Open	N/A	At the end of 2014 this site had used 13% of it's timeframe, and recruited 25% of its target, therefore is currently on target.